Pfizer: Very bad prospects!

Pfizer: Investors are disgruntled

The discussions around Pfizer on social media platforms give a clear signal about the assessments and moods around the title. Currently, negative opinions are piling up overall in the comments and opinions in the past two weeks. In addition, predominantly negative topics were raised around the value in recent days. This leads our editorial team to the conclusion that the company should be classified as a “sell”. Finally, eight trading signals can also be identified at this level in the past period. The picture shows 0 buy and 8 sell signals. This result ultimately leads to a classification as a “Sell” share. In summary, the editorial team is thus of the opinion that the Pfizer share is appropriately valued at “Sell” in relation to investor sentiment.

What is Pfizer’s upside potential?

In the past 12 months, analysts have given Pfizer 2 buy ratings, 8 hold ratings and 0 sell ratings. In the long term, the title thus receives a “Hold” rating from institutional sources. This is also the view of the analysts, who recently issued a rating for the stock – the average recommendation for Pfizer from the last month is also “Hold” (2 Buy, 3 Hold, 0 Sell). Finally, the analysts are also concerned with the current price of $49.49. On this basis, they expect a 10.01 percent move and generate a median price target at $54.44. We consider this development as a “Buy” assessment. In this respect, the overall rating by institutional analysts is “Hold”.

Pfizer: How high is the dividend yield?

Relative to the current price level, the dividend yield is 3.27 percent, which is 1.65 percent above the industry average (BrancheArzneimittel, 1.62). The Pfizer share therefore receives a “Buy” rating from the editorial team for this dividend policy. The dividend yield relates the dividend to the current share price.

How does the fundamental analysis judge?

With a price-earnings ratio (P/E ratio) of 8, Pfizer’s share is valued 88 percent lower than comparable companies in the “Pharmaceuticals” sector (67.76), based on today’s quotations. This ratio in turn signals an undervaluation. This results in a “buy” rating from the perspective of fundamental analysis.

Where do the moving averages run?

A look at the chart performance of a stock using the moving average can be used to determine the current trend of the security. Let’s look at the moving average of the closing price of Pfizer stock from the last 200 trading days. This value is currently $49.06. Thus, the last closing price (USD 49.49) is at a similar level (difference +0.88 percent). On this basis, we thus rate the share as a “Hold” How does this calculation look if the moving average is determined on the basis of the last 50 trading days? For this stock ($45.69), the last closing price is above the moving average (+8.32 percent). Thus, this case results in a different rating for Pfizer stock, and that is a “buy” rating. Thus, the Pfizer stock is given a “Buy” rating for the simple chart technique in total.

How much is the stock in discussion?

An evaluation of the rate of change in sentiment as well as the intensity of discussion reveals the following pictureDuring the past month, there has been no significant trend in investor sentiment. Therefore, we rate this item as “Hold”. Let’s look at the intensity of discussions from last month. This provides information on whether a stock tends to receive a lot or little attention. The company was discussed less than before and moved out of investors’ focus. This leads to a “sell” rating. This gives Pfizer stock a “sell” rating.

Share price return not in line with market

Pfizer posted a performance of -0.91 percent over the past 12 months. Similar stocks in the “pharmaceuticals” sector have risen an average of 26.23 percent, meaning Pfizer has underperformed the sector by -27.14 percent. The “health care” sector had a median return of 25.82 percent over the past year. Pfizer was 26.73 percent below that average. The underperformance in both industry and sector comparisons leads to a “sell” rating in this category.